Abstract
The treatment of choice for patients with severe aplastic anaemia (SAA) includes immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin A. However, the optimal dose for rabbit ATG has yet to be established. We herein report the first prospective, randomized, multicentre study comparing two doses of rabbit ATG in patients with SAA. Patients with SAA who required initial IST in Japan (n=89), China (n=85) and Korea (n=48) were enrolled between May 2012 and October 2017. A 1:1 block randomization was employed for two doses of rabbit ATG. In total, 222 patients were randomized, with 112 patients receiving 2·5mg/kg and 110 receiving 3·5mg/kg of rabbit ATG for 5days. The primary endpoint was the haematological response at day 180. After 6months, no significant difference in response rates was observed between the 2·5 and 3·5mg/kg groups (49% vs. 48%, P=0·894). Overall survival at 3years was similar between the two groups [85% (95% confidence interval [CI], 76%-91%) vs. 91% (95% CI, 82%-96%); P=0·107]. The current study revealed no significant differences in the efficacy and safety between the 2·5 and 3·5mg/kg doses of rabbit ATG in patients with SAA. Trial registration: UMIN000011134.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
